ADGM vs AIDX

Adagio Medical Holdings, Inc vs 20/20 Biolabs, Inc. — Valuation Comparison 2026

ADGM

Medical Devices
Adagio Medical Holdings, Inc
Quality
3.7
out of 10
Value Trap
37
LOW
Price
$0.72
Last close
Models
5/13
Active
VS

AIDX

Medical Devices
20/20 Biolabs, Inc.
Quality
5.6
out of 10
Value Trap
Price
$0.87
Last close
Models
10/13
Active

Model-by-Model Comparison

ModelType ADGM Fair ValueADGM Upside AIDX Fair ValueAIDX Upside
Bayesian DCF Intrinsic $0.12 -92.0% $0.40 -53.6%
Earnings Power Value Intrinsic $0.22 -86.1%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.34 +85.1% $0.07 -95.5%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ADGM vs AIDX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ADGM vs AIDX — Which Stock Is More Undervalued?

AIDX scores higher with a 5.6/10 quality rating vs ADGM's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Adagio Medical Holdings, Inc (ADGM) and 20/20 Biolabs, Inc. (AIDX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ADGM currently trades at $0.72 with a QOC of 3.7/10, while AIDX trades at $0.87 with a QOC of 5.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).